Riluzole

Subscribe to Selected New Research on Riluzole

290 relevant articles (27 outcomes, 71 trials/studies) found for this Drug

Description: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.

Also Known As:

2-Amino-6-trifluoromethoxybenzothiazole; Aventis Behring Brand of Riluzole; Aventis Brand of Riluzole; Impax Brand of Riluzole; PK-26124; RP-54274; Rhone-Poulenc Rorer Brand of Riluzole; Rilutek; 2 Amino 6 trifluoromethoxybenzothiazole; PK 26124; PK26124; RP 54274; RP54274; Rhone Poulenc Rorer Brand of Riluzole; Riluzole Aventis Brand; Riluzole Impax Brand

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Sulfur Compounds: 82

Thiazoles: 12

Riluzole: 290

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

2-Ring Heterocyclic Compounds

Benzothiazoles: 10

Riluzole: 290

Experts

1.	Coric, Vladimir: 6 articles (06/2008 - 05/2003)
2.	Pittenger, Christopher: 5 articles (06/2008 - 09/2005)
3.	Mitchell, J D: 5 articles (01/2007 - 01/2000)
4.	Miller, R G: 5 articles (01/2007 - 01/2000)
5.	Moore, D H: 5 articles (01/2007 - 01/2000)
6.	Krystal, John H: 4 articles (01/2008 - 05/2003)
7.	Wasylink, Suzanne: 3 articles (06/2008 - 05/2003)
8.	Groeneveld, G J: 3 articles (05/2008 - 11/2004)
9.	van Kan, H J M: 3 articles (05/2008 - 11/2004)
10.	van den Berg, L H: 3 articles (05/2008 - 11/2004)

Related Diseases

1.	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 11/07/2003 - "These results suggest that riluzole, a drug used in amyotrophic lateral sclerosis (ALS), might be beneficial for the treatment of MS." 04/01/2008 - "the current study the formation of riluzole-glucuronide was examined in amyotrophic lateral sclerosis (ALS) patients" 03/01/2007 - "Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy." 09/01/2003 - "SELECTION CRITERIA: Randomized trials of adults with diagnosis of amyotrophic lateral sclerosis (ALS), treated with riluzole or placebo" 04/01/2003 - "Riluzole is the only therapy proven in clinical trials to prolong amyotrophic lateral sclerosis (ALS) survival (approximately three months)" Order ALL the reference details at left...
2.	Ischemia 11/10/2000 - "We investigated the efficacy of low dose riluzole, which was similar to the dose used in human trials, in animal model of global ischemia" 01/12/1993 - "The ischemia-induced neurological and memory impairments were not improved by riluzole" 11/10/2000 - "Riluzole (0.8 mg/kg) were injected intraperitoneally 30min before ischemia" 11/10/2000 - "Neuroprotective effect of low dose riluzole in gerbil model of transient global ischemia." 11/01/2000 - "CONCLUSIONS: The data indicate that treatment with riluzole can increase the tolerance of spinal cord motoneurons to a period of normothermic ischemia" Order ALL the reference details at left...
3.	Wounds and Injuries (Trauma) 12/01/2000 - "These data demonstrate that riluzole has protective effects on DA neurons in vitro against neuronal injuries induced by (a) impairment of cellular energy metabolism and/or (b) oxidative stress" 12/01/2000 - "However, these neurochemical parameters as measured in cisternal CSF failed to reflect trauma-dependent increases in severity of tissue damage and did not reveal riluzole-mediated neuroprotection" 12/01/2000 - "In rats with a more severe trauma (1.5-mm penetration depth), the neuroprotective effect of riluzole failed to reach statistical significance" 12/01/2000 - "Experiments were performed at two different degrees of trauma severity as defined by penetration depth of the impactor rod (1 vs. 1.5 mm) with the aim of investigating impact of severity of tissue damage on the neuroprotective potential of riluzole" 01/31/1996 - "Animals received riluzole (2 mg kg-1) or vehicle twice daily for 10 days following the trauma" Order ALL the reference details at left...
4.	Disease Progression 01/01/2005 - "Moreover, the therapeutic efficacy of riluzole, the only drug proven to slow disease progression in ALS, is most likely related to its anti-excitotoxic properties" 05/01/2008 - "An association study of riluzole serum concentration and survival and disease progression in patients with ALS." 05/01/2008 - "No significant association was found between riluzole AUCi and survival or disease progression." 05/01/2008 - "We then determined the association between riluzole AUCi and survival over a 5-year period, and between riluzole AUCi and disease progression, defined by the rates of decline of arm strength and vital lung capacity" 05/01/2008 - "Riluzole serum concentrations are associated with side effects and ALS symptoms, but the effect of the actual blood level of riluzole on disease progression and survival is unknown" Order ALL the reference details at left...
5.	Brain Ischemia (Cerebral Ischemia) 09/01/1997 - "Effects of riluzole on the evolution of focal cerebral ischemia: a magnetic resonance imaging study." 07/13/2005 - "Riluzole has been reported to protect against the deleterious effect of cerebral ischemia by blocking glutamatergic neurotransmission" 01/12/1993 - "Effect of riluzole on focal cerebral ischemia in rats." 11/10/2000 - "Riluzole is a neuroprotective agent the efficacy of which was proven in amyotrophic lateral sclerosis in human and in animal models of cerebral ischemia" 01/01/1998 - "The aim of the present study was to examine the ability of riluzole to inhibit glutamate release during episodes of transient global cerebral ischemia" Order ALL the reference details at left...

Related Drugs and Biologics

1.	N-Methylaspartate (NMDA)
2.	Glutamic Acid (Glutamate)
3.	Riluzole
4.	Ketamine
5.	Sodium Channels (Sodium Channel)
6.	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
7.	Sodium Channel Blockers (Potassium Sparing Diuretics)
8.	Neuroprotective Agents
9.	Phenytoin (Dilantin)
10.	Mexiletine (Mexitil)

Related Therapies and Procedures

1.	Tracheostomy
2.	Drug Therapy (Chemotherapy)
3.	Anesthesia
4.	Surgical Decompression
5.	Transplantation (Transplant Recipients)

Best Treatments:
Research Summary Report
on Amyotrophic Lateral Sclerosis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 63 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>